Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Plos One
|
December 19, 2013
Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from southern France
Estelle Masseret, Sandra Banack, Farid Boumédiène, et al.
Molecular Neurobiology
|
March 1, 2017
Liver X Receptor Genes Variants Modulate ALS Phenotype
Kevin Mouzat, Nicolas Molinari, Jovana Kantar, et al.
Frontiers in Neuroscience
|
May 16, 2020
Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort
Florence Esselin, Kevin Mouzat, Anne Polge, et al.
Annals of Clinical and Translational Neurology
|
February 15, 2020
Rhythm disturbances as a potential early marker of Parkinson's disease in idiopathic REM sleep behavior disorder
Valérie Cochen De Cock, Delphine de Verbizier, Marie Christine Picot, et al.
Ebiomedicine
|
July 12, 2020
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial
William Camu, Marius Mickunas, Jean-Luc Veyrune, et al.
Brain Communications
|
August 19, 2021
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2
Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.
BMJ Open
|
September 3, 2014
Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme
Aurélie Delzor, Philippe Couratier, Farid Boumédiène, et al.
Human Mutation
|
August 17, 2016
Mini-Exome Coupled to Read-Depth Based Copy Number Variation Analysis in Patients with Inherited Ataxias
Cecilia Marelli, Claire Guissart, Cecile Hubsch, et al.
Lancet (London, England)
|
May 12, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial
Gilbert Bensimon, P Nigel Leigh, Timothy Tree, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Plos One
|
December 19, 2013
Dietary BMAA exposure in an amyotrophic lateral sclerosis cluster from southern France
Estelle Masseret, Sandra Banack, Farid Boumédiène, et al.
Molecular Neurobiology
|
March 1, 2017
Liver X Receptor Genes Variants Modulate ALS Phenotype
Kevin Mouzat, Nicolas Molinari, Jovana Kantar, et al.
Frontiers in Neuroscience
|
May 16, 2020
Clinical Phenotype and Inheritance in Patients With C9ORF72 Hexanucleotide Repeat Expansion: Results From a Large French Cohort
Florence Esselin, Kevin Mouzat, Anne Polge, et al.
Annals of Clinical and Translational Neurology
|
February 15, 2020
Rhythm disturbances as a potential early marker of Parkinson's disease in idiopathic REM sleep behavior disorder
Valérie Cochen De Cock, Delphine de Verbizier, Marie Christine Picot, et al.
Ebiomedicine
|
July 12, 2020
Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial
William Camu, Marius Mickunas, Jean-Luc Veyrune, et al.
Brain Communications
|
August 19, 2021
Amyotrophic lateral sclerosis transcriptomics reveals immunological effects of low-dose interleukin-2
Ilaria Giovannelli, Nadhim Bayatti, Abigail Brown, et al.
BMJ Open
|
September 3, 2014
Searching for a link between the L-BMAA neurotoxin and amyotrophic lateral sclerosis: a study protocol of the French BMAALS programme
Aurélie Delzor, Philippe Couratier, Farid Boumédiène, et al.
Human Mutation
|
August 17, 2016
Mini-Exome Coupled to Read-Depth Based Copy Number Variation Analysis in Patients with Inherited Ataxias
Cecilia Marelli, Claire Guissart, Cecile Hubsch, et al.
Lancet (London, England)
|
May 12, 2025
Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole (MIROCALS): a phase 2b, double-blind, randomised, placebo-controlled trial
Gilbert Bensimon, P Nigel Leigh, Timothy Tree, et al.
Page
of 2